Two pharmaceutical firms fined by Chinese market regulator for monopolistic practices
MLex Summary: Grand Pharmaceutical (China) and Wuhan Healcare Pharmaceuticals have been fined by China’s State Administration for Market Regulation for reaching and implementing a monopolistic agreement under which Wuhan Healcare received...To view the full article, register now.
Already a subscriber? Click here to view full article